Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

“It is expected that manufacturing the oral peptide should be easier from a ... Both Novo Nordisk and Eli Lilly have faced significant supply constraints over the past two years as demand ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...